Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL

  • Ahn, Jae Hyun (Department of Urology and Biomedical Research Institute, Pusan National University Hospital) ;
  • Lee, Jeong Zoo (Department of Urology and Biomedical Research Institute, Pusan National University Hospital) ;
  • Chung, Moon Kee (Department of Urology and Biomedical Research Institute, Pusan National University Hospital) ;
  • Ha, Hong Koo (Department of Urology and Biomedical Research Institute, Pusan National University Hospital)
  • Received : 2013.01.07
  • Accepted : 2014.01.08
  • Published : 2014.03.10
⟨ Previous Next ⟩

Abstract

Although prostate-specific antigen (PSA) is a very useful screening tool, prostate biopsy is still necessary to confirm prostate cancer (PCA). However, it is reported that PSA is associated with a high false-positive rate and prostate biopsy also has various procedure-related complications. Therefore, the authors have devised a nomogram, which can be used to estimate the risk of PCA, using available clinical data for men with a serum PSA less than 10 ng/mL. Prostate biopsies were obtained from 2,139 patients from January 1998 to March 2011. Of them, 1,171 patients with a serum PSA less than 10 ng/mL were only included in this study. Patient age, PSA, free PSA, prostate volume, PSA density and percent free PSA ratio were analyzed. Among 1,171 patients, 255 patients (21.8%) were diagnosed as PCA. Multivariate analyses showed that patient age, prostate volume, PSA and percent free PSA had statistically significant relationships with PCA (P < 0.05) and were used as nomogram predictor variables. The area under the (ROC) curve for all factors in a model predicting PCA was 0.759 (95% CI, 0.716-0.803).

Keywords

References

  1. American Cancer Society. Cancer facts and figures 2008. Available at http://www.cancer.org/acs/groups/content/@nho/documents/document/2008cafffinalsecuredpdf.pdf [accessed on 15 February 2013].
  2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8. https://doi.org/10.1093/annonc/mdi098
  3. National Cancer Center. Cancer facts and figures 2011. Available at http://www.cancer.go.kr/ncic/cics_g/cics_g02/cics_g027/1647906_6065.html [accessed on 15 February 2013].
  4. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9. https://doi.org/10.1056/NEJMoa0810696
  5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61. https://doi.org/10.1056/NEJM199104253241702
  6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8. https://doi.org/10.1056/NEJMoa0810084
  7. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46. https://doi.org/10.1056/NEJMoa031918
  8. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schroder FH, Scattoni V. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010; 58: 851-64. https://doi.org/10.1016/j.eururo.2010.08.041
  9. Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013; 63: 521-7. https://doi.org/10.1016/j.eururo.2012.06.003
  10. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003; 61: 589-95. https://doi.org/10.1016/S0090-4295(02)02287-2
  11. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007; 18: 279-85. https://doi.org/10.1007/s10552-006-0087-6
  12. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
  13. Ferro MA, Barnes I, Roberts JB, Smith PJ. Tumour markers in prostatic carcinoma: a comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987; 60: 69-73. https://doi.org/10.1111/j.1464-410X.1987.tb09137.x
  14. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-4. https://doi.org/10.1016/j.juro.2011.06.057
  15. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-4. https://doi.org/10.1016/j.eururo.2011.12.058
  16. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963-8. https://doi.org/10.1016/j.juro.2009.11.043
  17. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int J Urol 2008; 15: 598-603. https://doi.org/10.1111/j.1442-2042.2008.02058.x
  18. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998; 52: 455-61. https://doi.org/10.1016/S0090-4295(98)00205-2
  19. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 1999; 54: 709-13. https://doi.org/10.1016/S0090-4295(99)00213-7
  20. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173: 1930-4. https://doi.org/10.1097/01.ju.0000158039.94467.5d
  21. Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. Urology 1997; 50: 665-72. https://doi.org/10.1016/S0090-4295(97)00451-2
  22. Zaytoun OM, Kattan MW, Moussa AS, Li J, Yu C, Jones JS. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. Urology 2011; 78: 392-8. https://doi.org/10.1016/j.urology.2011.04.042

Cited by

  1. Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 ng/ml via a New Model to Reduce Unnecessary Prostate Biopsies vol.9, pp.9, 2014, https://doi.org/10.1371/journal.pone.0106933
  2. Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA l vol.2, pp.2, 2014, https://doi.org/10.1016/j.ajur.2015.04.023
  3. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL vol.57, pp.3, 2014, https://doi.org/10.3349/ymj.2016.57.3.565
  4. The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers vol.35, pp.3, 2014, https://doi.org/10.14366/usg.15065
  5. Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population vol.143, pp.7, 2014, https://doi.org/10.1007/s00432-017-2389-3
  6. Nomogram for predicting the probability of the positive outcome of prostate biopsies among Ghanaian men vol.24, pp.1, 2018, https://doi.org/10.1016/j.afju.2017.09.004
  7. A novel nomogram of naïve Bayesian model for prevalence of cardiovascular disease vol.25, pp.3, 2014, https://doi.org/10.29220/csam.2018.25.3.297
  8. Novel nomogram for screening the risk of developing diabetes in a Korean population vol.142, pp.None, 2014, https://doi.org/10.1016/j.diabres.2018.05.036
  9. Age, prostate volume, prostate-specific antigen and prostate-specific antigen density as predictor factors in results of transrectal ultrasonography-guided prostate biopsy vol.8, pp.None, 2019, https://doi.org/10.12688/f1000research.18892.1
  10. Prostate cancer detection rate according to lesion visibility using ultrasound and MRI vol.74, pp.6, 2014, https://doi.org/10.1016/j.crad.2019.02.002
  11. Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy vol.100, pp.50, 2021, https://doi.org/10.1097/md.0000000000028196